Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Sheejith Kakkunnath"'
Autor:
Shubhadeep D Sinha, Ghanashyam Biswas, Bala Reddy Bheemareddy, Sreenivasa Chary, Pankaj Thakur, Minish Jain, Tanveer Maksud, Suraj Pawar, Koushik Chatterjee, Murali Krishna Voonna, Anil Goel, Krishna Chaitanya Puligundla, Kuntegowdanahalli Chinnagiriyappa Lakshmaiah, Leela Talluri, Ramya Vattipalli, Sheejith Kakkunnath
Publikováno v:
Cancer Informatics, Vol 22 (2023)
Objective: The aim of this study was to evaluate the post-marketing safety, tolerability, immunogenicity and efficacy of Bevacizumab (manufactured by Hetero Biopharma) in a broader population of patients with solid tumors. Patients And Methods: This
Externí odkaz:
https://doaj.org/article/25def5a4029d43afa85aaee5274c5cf2
Autor:
Bala Reddy Bheema Reddy, Leela Talluri, Vamsi Krishna Bandi, Sreenivasa Chary, Pankaj Thakur, Shubhadeep Sinha, Sheejith Kakkunnath
Publikováno v:
Cureus
Background This post-marketing surveillance (PMS), observational, prospective, safety study evaluated the safety, tolerability, and long-term immunogenicity of prescribed usage of Darbepoetin alfa (DA-α, manufactured by Hetero Biopharma, Hyderabad,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b686f2338cab08c9b002639bff883d6f
https://pubmed.ncbi.nlm.nih.gov/34079677
https://pubmed.ncbi.nlm.nih.gov/34079677
Autor:
Sheejith Kakkunnath, Leela Talluri, Shubhadeep Sinha, Vamsi Krishna Bandi, Sreenivasa Chary, Pankaj Thakur, Priyanka Das, Srinivasa Sanka, Bala Reddy Bheemareddy
Background This phase IV, post–authorisation safety & efficacy study evaluated the safety, immunogenicity and tolerability of prescribed usage of Darbepoetin alfa, (DA-α, manufactured by Hetero Biopharma) for the treatment of symptomatic anemia in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::edbba7eb2f5c24b0a0dc54c5f4641c28
https://doi.org/10.21203/rs.3.rs-23193/v1
https://doi.org/10.21203/rs.3.rs-23193/v1
